| Literature DB >> 11479399 |
Abstract
Gabapentin (GBP) has gained wide acceptance in the treatment of pain, migraine, bipolar illness, and epilepsy. It has a relatively benign side effect profile, lacks significant drug interactions, is not liver metabolized, and is renally excreted. Herein three cases are presented that demonstrate withdrawal symptoms after abrupt discontinuation of GBP. Clinicians are encouraged to taper GBP dosage, especially when patients have taken high doses, and to warn patients of possible adverse effects of abruptly discontinuing GBP themselves.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11479399 DOI: 10.1097/00002826-200107000-00011
Source DB: PubMed Journal: Clin Neuropharmacol ISSN: 0362-5664 Impact factor: 1.592